{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["18(1)"],"submitter":["Totte J"],"funding":["Micreos Human Health bv"],"pubmed_abstract":["<h4>Background</h4>Atopic dermatitis (AD) is associated with reduced skin microbial diversity and overgrowth of Staphylococcus (S.) aureus. However, the importance of S. aureus colonisation in the complex pathogenesis remains unclear and studies on the effect of anti-staphylococcal therapy in non-infected AD show contradictory results. Long-term interventions against S. aureus might be needed to restore the microbial balance, but carry the risk of bacterial resistance induction. Staphefekt, an engineered bacteriophage endolysin, specifically kills S. aureus leaving other skin commensals unharmed. Bacterial resistance towards endolysins has not been reported, nor is it expected, which allows us to study its effect as long-term anti-staphylococcal treatment in non-infected AD.<h4>Methods</h4"],"journal":["Trials"],"pagination":["404"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC5580294"],"repository":["biostudies-literature"],"pubmed_title":["Targeted anti-staphylococcal therapy with endolysins in atopic dermatitis and the effect on steroid use, disease severity and the microbiome: study protocol for a randomized controlled trial (MAAS trial)."],"pmcid":["PMC5580294"],"pubmed_authors":["Pasmans S","Pardo L","Totte J","de Wit J","Schuren F","van Doorn M"],"additional_accession":[]},"is_claimable":false,"name":"Targeted anti-staphylococcal therapy with endolysins in atopic dermatitis and the effect on steroid use, disease severity and the microbiome: study protocol for a randomized controlled trial (MAAS trial).","description":"<h4>Background</h4>Atopic dermatitis (AD) is associated with reduced skin microbial diversity and overgrowth of Staphylococcus (S.) aureus. However, the importance of S. aureus colonisation in the complex pathogenesis remains unclear and studies on the effect of anti-staphylococcal therapy in non-infected AD show contradictory results. Long-term interventions against S. aureus might be needed to restore the microbial balance, but carry the risk of bacterial resistance induction. Staphefekt, an engineered bacteriophage endolysin, specifically kills S. aureus leaving other skin commensals unharmed. Bacterial resistance towards endolysins has not been reported, nor is it expected, which allows us to study its effect as long-term anti-staphylococcal treatment in non-infected AD.<h4>Methods</h4","dates":{"release":"2017-01-01T00:00:00Z","publication":"2017 Aug","modification":"2026-07-15T19:29:48.5Z","creation":"2019-03-27T02:55:10Z"},"accession":"S-EPMC5580294","cross_references":{"pubmed":["28859690"],"doi":["10.1186/s13063-017-2118-x"]}}